PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34653270-0	2022	Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series.	midostaurin	7-18	fms related receptor tyrosine kinase 3	Homo sapiens	58-62	
34653270-3	2022	Regarding FLT3-positive MPAL, only one case treated with midostaurin has been published to date.	midostaurin	57-68	fms related receptor tyrosine kinase 3	Homo sapiens	10-14	
34653270-4	2022	Here, we report the successful use of midostaurin to treat three FLT3-positive MPAL T/myeloid and B/myeloid patients.	midostaurin	38-49	fms related receptor tyrosine kinase 3	Homo sapiens	65-69	
34653270-8	2022	These results suggest that the addition of midostaurin during induction and consolidation therapy may represent a treatment option for FLT3-positive MPAL.	midostaurin	43-54	fms related receptor tyrosine kinase 3	Homo sapiens	135-139